scholarly journals The Wound Healing Peptide, AES16-2M, Ameliorates Atopic Dermatitis In Vivo

Molecules ◽  
2021 ◽  
Vol 26 (4) ◽  
pp. 1168
Author(s):  
Myun Soo Kim ◽  
Jisun Song ◽  
Sunyoung Park ◽  
Tae Sung Kim ◽  
Hyun Jeong Park ◽  
...  
Keyword(s):  
Wound Healing ◽  
Atopic Dermatitis ◽  
Side Effects ◽  
Low Cost ◽  
Calcineurin Inhibitors ◽  
Human Keratinocytes ◽  
Peripheral Lymph ◽  
Therapeutic Peptides ◽  
Peptide Materials

Peptide materials have recently been considered for use in various industrial fields. Because of their efficacy, safety, and low cost, therapeutic peptides are studied for various diseases, including atopic dermatitis (AD). AD is a common inflammatory skin disease impairing the patient’s quality of life. Various therapies, such as treatments with corticosteroids, calcineurin inhibitors, and antibody drugs, have been applied, but numerous side effects have been reported, including skin atrophy, burning, and infection. In the case of antibody drugs, immunogenicity against the drugs can be a problem. To overcome these side effects, small peptides are considered therapeutic agents. We previously identified the small wound healing peptide AES16-2M with a sequence of REGRT, and examined its effects on AD in this study. Interestingly, the administration of AES16-2M downregulated the AD disease score, ear thickness, serum IgE, and thymic stromal lymphopoietin (TSLP) in AD mice. The thickness of the epidermal layer was also improved by AES16-2M treatment. In addition, quantities of IL-4-, IL-13-, and IL-17-producing CD4 T cells from peripheral lymph nodes and spleens were reduced by injection of AES16-2M. Furthermore, the expression of TSLP was significantly reduced in AES16-2M-treated human keratinocytes. Therefore, these results suggest that AES16-2M can be a novel candidate for AD treatment.

Accelerated Wound Healing Induced by a Novel Amphibian Peptide (OA-FF10)

2019 ◽  
Vol 26 (4) ◽  
pp. 261-270 ◽  
Author(s):  
Naixin Liu ◽  
Zhe Li ◽  
Buliang Meng ◽  
Wenxin Bian ◽  
Xiaojie Li ◽  
...  
Keyword(s):  
Wound Healing ◽  
Chronic Wounds ◽  
Low Cost ◽  
Financial Burden ◽  
Human Keratinocytes ◽  
Critical Issue ◽  
Disulfide Bridge ◽  
Toxic Activity

Background: Despite the continued development of modern medicine, chronic wounds are still a critical issue in clinical treatment, placing a great physiological, psychological, and financial burden on patients. Researchers have investigated many methods to solve this problem, with bioactive peptides gaining increasing attention due to their considerable advantages and diverse functions, as well as low cost, simple storage, and easy transportation. Methods: In this research, a novel peptide (named OA-FF10) was identified from the skin secretions of the odorous frog species Odorrana andersonii. The sequence of mature OA-FF10 was “FFTTSCRSGC”, which was produced by the post-translational processing of a 61-residue prepropeptide. Results: Similar to most frog peptides, OA-FF10 showed an intramolecular disulfide bridge at the C-terminus. OA-FF10 demonstrated no antibacterial, antioxidant, hemolytic, or acute toxic activity, but promoted wound healing and proliferation of human keratinocytes (HaCaT) both time- and dose-dependently. Furthermore, while OA-FF10 had no effect on wound healing of Human Skin Fibroblasts (HSF), it did accelerate healing in a full-thickness skin-wound mouse model. Conclusion: Our research revealed the strong wound-healing activity of OA-FF10 in vivo and in vitro, thus providing a new candidate for the development of novel wound-healing drugs.

scholarly journals Human Keratinocyte Growth and Differentiation on Acellular Porcine Dermal Matrix in relation to Wound Healing Potential

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Robert Zajicek ◽  
Vaclav Mandys ◽  
Ondrej Mestak ◽  
Jan Sevcik ◽  
Radana Königova ◽  
...  
Keyword(s):  
Wound Healing ◽  
Human Keratinocytes ◽  
Dermal Matrix ◽  
Keratinocyte Proliferation ◽  
Proliferation And Differentiation ◽  
A Cell ◽  
Cell Culture Assay ◽  
Air Liquid Interface

A number of implantable biomaterials derived from animal tissues are now used in modern surgery. Xe-Derma is a dry, sterile, acellular porcine dermis. It has a remarkable healing effect on burns and other wounds. Our hypothesis was that the natural biological structure of Xe-Derma plays an important role in keratinocyte proliferation and formation of epidermal architecturein vitroas well asin vivo. The bioactivity of Xe-Derma was studied by a cell culture assay. We analyzed growth and differentiation of human keratinocytes culturedin vitroon Xe-Derma, and we compared the results with formation of neoepidermis in the deep dermal wounds treated with Xe-Derma. Keratinocytes cultured on Xe-Derma submerged in the culture medium achieved confluence in 7–10 days. After lifting the cultures to the air-liquid interface, the keratinocytes were stratified and differentiated within one week, forming an epidermis with basal, spinous, granular, and stratum corneum layers. Immunohistochemical detection of high-molecular weight cytokeratins (HMW CKs), CD29, p63, and involucrin confirmed the similarity of organization and differentiation of the cultured epidermal cells to the normal epidermis. The results suggest that the firm natural structure of Xe-Derma stimulates proliferation and differentiation of human primary keratinocytes and by this way improves wound healing.

scholarly journals Calmodulin-Like Protein Upregulates Myosin-10 in Human Keratinocytes and Is Regulated during Epidermal Wound Healing In Vivo

2009 ◽  
Vol 129 (3) ◽  
pp. 765-769 ◽  
Author(s):  
Richard D. Bennett ◽  
Amy S. Mauer ◽  
Mark R. Pittelkow ◽  
Emanuel E. Strehler
Keyword(s):  
Wound Healing ◽  
Human Keratinocytes

scholarly journals A novel method of screening combinations of angiostatics identifies bevacizumab and temsirolimus as synergistic inhibitors of glioma-induced angiogenesis

PLoS ONE ◽  
2021 ◽  
Vol 16 (6) ◽  
pp. e0252233
Author(s):  
Michael I. Dorrell ◽  
Heidi R. Kast-Woelbern ◽  
Ryan T. Botts ◽  
Stephen A. Bravo ◽  
Jacob R. Tremblay ◽  
...  
Keyword(s):  
Side Effects ◽  
Tumor Angiogenesis ◽  
Clinical Success ◽  
Low Cost ◽  
Chorioallantoic Membrane ◽  
Cellular Interactions ◽  
Compensatory Mechanisms ◽  
Chick Chorioallantoic Membrane

Tumor angiogenesis is critical for the growth and progression of cancer. As such, angiostasis is a treatment modality for cancer with potential utility for multiple types of cancer and fewer side effects. However, clinical success of angiostatic monotherapies has been moderate, at best, causing angiostatic treatments to lose their early luster. Previous studies demonstrated compensatory mechanisms that drive tumor vascularization despite the use of angiostatic monotherapies, as well as the potential for combination angiostatic therapies to overcome these compensatory mechanisms. We screened clinically approved angiostatics to identify specific combinations that confer potent inhibition of tumor-induced angiogenesis. We used a novel modification of the ex ovo chick chorioallantoic membrane (CAM) model that combined confocal and automated analyses to quantify tumor angiogenesis induced by glioblastoma tumor onplants. This model is advantageous due to its low cost and moderate throughput capabilities, while maintaining complex in vivo cellular interactions that are difficult to replicate in vitro. After screening multiple combinations, we determined that glioblastoma-induced angiogenesis was significantly reduced using a combination of bevacizumab (Avastin®) and temsirolimus (Torisel®) at doses below those where neither monotherapy demonstrated activity. These preliminary results were verified extensively, with this combination therapy effective even at concentrations further reduced 10-fold with a CI value of 2.42E-5, demonstrating high levels of synergy. Thus, combining bevacizumab and temsirolimus has great potential to increase the efficacy of angiostatic therapy and lower required dosing for improved clinical success and reduced side effects in glioblastoma patients.

Recent Approaches on Novel Topical Delivery Systems for Atopic Dermatitis Treatment

2020 ◽  
Vol 14 ◽  
Author(s):  
Emine Kahraman ◽  
Neriman Aydilek ◽  
Sevgi Güngör
Keyword(s):  
Drug Delivery ◽  
Atopic Dermatitis ◽  
Side Effects ◽  
Drug Delivery Systems ◽  
Skin Permeation ◽  
Calcineurin Inhibitors ◽  
Chronic Inflammatory Disease ◽  
Delivery Systems ◽  
Drug Substances ◽  
Novel Drug

: Atopic dermatitis is a chronic inflammatory disease of the skin, which is characterized by itching, erythema and eczematous lacerations. It affects about 10 % of adults and approximately 15-20 % of children in the worldwide. As a result of genetic, immunologic and environmental factors, the disease manifests itself with impaired stratum corneum barrier and then immunological responses. Topical administration of corticosteroids and calcineurin inhibitors are currently used as the first strategy in the management of disease. However, they have low skin bioavailability and some side effects. The nano-carriers as novel drug delivery systems could overcome limitations of conventional dosage forms, owing to increment of poorly soluble drug' solubility, then its thermodynamic activity and consequently its skin permeation. Also, side effects of the drug substances on the skin could be reduced by the nano sized drug delivery systems, due to encapsulation of the drug in the nano-carriers and targeted drug delivery of drug substances to the inflammated skin areas. Thereby, there have been available a numerous of research studies and patents regarding use of the nano-carriers in the management of atopic dermatitis. This review focuses on the mechanism of disease and, developments on the nano-carrier based on novel drug release systems of in the management of atopic dermatitis.

Nanotechnology-based Therapeutic Applications: In Vitro, In Vivo Clinical Studies for Diabetic Wound Healing

2021 ◽  
Author(s):  
Sheikh Tanzina Haque ◽  
Subbroto Kumar Saha ◽  
Md. Enamul Haque ◽  
Nirupam Biswas
Keyword(s):  
Wound Healing ◽  
Side Effects ◽  
Conventional Treatment ◽  
Treatment Modalities ◽  
Diabetic Wound ◽  
Chronic Complications ◽  
Diabetic Wound Healing ◽  
Diabetic Wounds

Diabetic wounds often presage chronic complications that are difficult to treat. Unfortunately, existing conventional treatment modalities often warrant unpremeditated side effects, given the need to develop alternative therapeutic phenotypes that...

scholarly journals A Novel Herbal Hydrogel Formulation of Moringa oleifera for Wound Healing

Plants ◽  
2020 ◽  
Vol 10 (1) ◽  
pp. 25
Author(s):  
Aaliya Ali ◽  
Prakrati Garg ◽  
Rohit Goyal ◽  
Gurjot Kaur ◽  
Xiangkai Li ◽  
...  
Keyword(s):  
Wound Healing ◽  
Side Effects ◽  
Moringa Oleifera ◽  
Antimicrobial Activities ◽  
Hexane Extract ◽  
Hydrogel Formulation ◽  
Incision Wound ◽  
Antioxidant And Antimicrobial Activities

Treatment of wounds is essential as the wound can also be lethal at some point in time if not healed properly. Ethnomedicinal plants can treat wounds as they have no side effects, whereas, in the case of chemical drugs, the side effects are on the rise. In this study, seeds of Moringa oleifera which is the essential ethnomedicinal plant, were studied for wound healing efficacy. The study was planned for the assessment of in vitro (antioxidant and antimicrobial activities) and in vivo (excision and incision wound healing models) wound healing efficacy of n-hexane extract and hydrogels of Moringa oleifera seeds. The antioxidant and antimicrobial activities were assessed by DPPH free radical scavenging assay and Agar well diffusion method, respectively. In excision and incision wound models, Swiss albino mice were used for wound healing efficacy of hydrogels, i.e., 5% and 10% hexane extracts of Moringa oleifera seeds. The n-hexane extract showed antioxidant as well as antibacterial activities. Moreover, the hydrogels formulated using n-hexane extract of Moringa oleifera seeds showed significant wound healing activity compared to both control and standard until the end of the protocol in both the models. Furthermore, the histopathological investigation confirmed the findings of accelerated regeneration of tissue accompanied by a decrease in inflammatory cells and increased vascularity of the immediate skin. The results (both in vitro and in vivo) claimed conclusively that our n-hexane hydrogel formulation of Moringa oleifera seeds might serve as an alternative therapy in skin restoration during wound healing.

scholarly journals Come together: bioelectric healing-on-a-chip

2020 ◽  
Author(s):  
Tom J. Zajdel ◽  
Gawoon Shim ◽  
Daniel J. Cohen
Keyword(s):  
Wound Healing ◽  
Cost Model ◽  
Low Cost ◽  
Experimental System ◽  
Model Systems ◽  
Device Development ◽  
Wound Healing Response ◽  
Field Geometry ◽  
On Chip

AbstractThere is a growing interest in bioelectric wound treatment and electrotaxis, the process by which cells detect an electric field and orient their migration along its direction, has emerged as a potential cornerstone of the endogenous wound healing response. Despite recognition of the importance of electrotaxis in wound healing, no experimental system to date demonstrates that the actual closing of a wound can be accelerated solely by the electrotaxis response itself, and in vivo systems are too complex to resolve cell migration from other healing stages such as proliferation and inflammation. This uncertainty has led to a lack of standardization between stimulation methods, model systems, and electrode technology required for device development. In this paper, we present a ‘healing-on-chip’ approach that is a standardized, low-cost, model for investigating electrically accelerated wound healing. Our device provides the first convergent field geometry used in a stimulation device. We validate this device by using electrical stimulation to close a 1.5 mm gap between two large (30 mm2) primary skin keratinocyte layers to double the rate of healing over an unstimulated tissue. This proves that convergent electrotaxis is both possible and can accelerate healing, and offers a new ‘healing-on-a-chip’ platform to explore future bioelectric interfaces.

scholarly journals OA-GL21, a novel bioactive peptide from Odorrana andersonii, accelerated the healing of skin wounds

2018 ◽  
Vol 38 (3) ◽  
Author(s):  
Wenxin Bian ◽  
Buliang Meng ◽  
Xiaojie Li ◽  
Siyuan Wang ◽  
Xiaoqing Cao ◽  
...  
Keyword(s):  
Wound Healing ◽  
Chronic Wounds ◽  
Antioxidant Activities ◽  
Low Cost ◽  
Human Fibroblasts ◽  
Human Keratinocytes ◽  
Skin Wound ◽  
New Drugs ◽  
Toxic Activity ◽  
Promote Wound Healing

Nowadays, the number of chronic trauma cases caused by a variety of factors such as the world’s population-ageing and chronic diseases is increasing steadily, and thus effective treatment for chronic wounds has become a severe clinical challenge, which also burdens the patient both physically and financially. Therefore, it is urgent to develop new drugs to accelerate the healing of wounds. Bioactive peptides, which are relatively low cost, easy to produce, store and transport, have become an excellent choice. In this research, we identified a novel peptide OA-GL21, with an amino acid sequence of ‘GLLSGHYGRVVSTQSGHYGRG’, from the skin secretions of Odorrana andersonii. Our results showed that OA-GL21 exerted the ability to promote wound healing of human keratinocytes (HaCaT) and human fibroblasts in a dose- and time-denpendent manner. However, OA-GL21 had no significant effect on the proliferation of these two cells. Significantly, OA-GL21 showed obvious ability to promote wound healing in the full-thickness skin wound model in dose- and scar-free manners. Further studies showed that OA-GL21 had no direct antibacterial, hemolytic, and acute toxic activity; it had weak antioxidant activities but high stability. In conclusion, this research proved the promoting effects of OA-GL21 on cellular and animal wounds, and thus provided a new peptide template for the development of wound-repairing drugs.

Sign in / Sign up

Export Citation Format

Share Document